Researchers Outline Interactions Between 93 Variables Influencing Social Relationships Among Young People pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Our NanoNews Digest Sponsors
Home > Press > New 3D-Bioprinter + Bioink Use Living Cells Straight From Culture Plate: Cell models mimicking natural tissue topography herald new era for biomedical research
Abstract:
The combination of a 2-Photon 3D-printer with an innovative hydrogel-based bioink allows the direct printing of 3D structures containing living cells at both the meso- and microscale. Developed by UpNano GmbH (Vienna, Austria), the NanoOne Bio is a printer based on the successful NanoOne range of laser-powered 2-Photon 3D-printers that are able to build structures across 12 orders of magnitude. The new hydrogel has been developed with Xpect INX (Ghent, Belgium), a spin-off in foundation specialized in the development of biocompatible materials for the 3D-(bio-)printing industry. It is the only commercially available resin that allows embedding living cells straight from a culture plate within highly precise 3D-printed structures for biological applications.
Search jobs Immunodiagnostics and Vaccine Development at Viravaxx AG Gain Momentum
Vienna (Austria), Jan 11, 2021. Fast-track development of vaccines against COVID-19 and other infectious diseases are facilitated by microarray-based assays for whole-proteome analysis and vaccine design platforms. Both have been developed by Viravaxx AG, and the company’s recent progress with its SARS-CoV-2 Interaction Assay offered a turning point.
Concomitantly, as of Jan 1, 2021, Viravaxx has recruited Dr. Helmut Brunar as its new CEO. Dr. Brunar brings vast expertise in vaccines, cell-therapies and diagnostic products to the company. Before joining Viravaxx, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. Dr. Brunar will take over from Dr. Rainer Henning, who has made invaluable contributions for